3 Reasons Exelixis Stock Could Deliver Market-Beating Returns Over the Next Decade [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
Exelixis (NASDAQ: EXEL) is a relatively small biotech company with big dreams -- to become, as its executives said at a presentation in December, a "top five solid tumor oncology company." The company has a blockbuster drug that's funding its pipeline efforts. Its shares are up more than 20% over the past year and up more than 97% over the past five years. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » There are plenty of reasons why the stock could continue to deliver market-beating returns, the biggest being a growing pipeline that will soon diversify its oncology treatment offerings. Here are three. 1. Cabozantinib keeps adding indications Exelixis' lead drug is cabozantinib -- which it sells as Cabometyx and Cometriq. Cabometyx, in tablet form, is a leading therapy to treat kidney cancer, and has als
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis, Inc. (EXEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
- Exelixis (EXEL) had its price target lowered by Royal Bank Of Canada from $46.00 to $43.00. They now have a "sector perform" rating on the stock.MarketBeat
- Exelixis (EXEL) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EXEL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "strong-buy" tMarketBeat
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March [Yahoo! Finance]Yahoo! Finance
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in MarchBusiness Wire
EXEL
Earnings
- 2/10/26 - Beat
EXEL
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- EXEL's page on the SEC website